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Abstract
Background: The therapeutic efficacy of stereotactic radiosurgery for glioblastoma is not well understood, and there needs
to be an effective biomarker to identify patients who might benefit from this treatment. This study investigated the efficacy
of computed tomography (CT) perfusion imaging as an early imaging biomarker of response to stereotactic radiosurgery in
a malignant rat glioma model.
Methods: Rats with orthotopic C6 glioma tumors received either mock irradiation (controls, N = 8) or stereotactic
radiosurgery (N = 25, 12 Gy in one fraction) delivered by Helical Tomotherapy. Twelve irradiated animals were sacrificed four
days after stereotactic radiosurgery to assess acute CT perfusion and histological changes, and 13 irradiated animals were
used to study survival. Irradiated animals with survival .15 days were designated as responders while those with survival #
15 days were non-responders. Longitudinal CT perfusion imaging was performed at baseline and regularly for eight weeks
post-baseline.
Results: Early signs of radiation-induced injury were observed on histology. There was an overall survival benefit following
stereotactic radiosurgery when compared to the controls (log-rank P,0.04). Responders to stereotactic radiosurgery
showed lower relative blood volume (rBV), and permeability-surface area (PS) product on day 7 post-stereotactic
radiosurgery when compared to controls and non-responders (P,0.05). rBV and PS on day 7 showed correlations with
overall survival (P,0.05), and were predictive of survival with 92% accuracy.
Conclusions: Response to stereotactic radiosurgery was heterogeneous, and early selection of responders and nonresponders was possible using CT perfusion imaging. Validation of CT perfusion indices for response assessment is
necessary before clinical implementation.
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response. Tumor progression is usually detected by increased
contrast-enhancement on gadolinium-enhanced T1-weighted MR
images, and T2-weighted or fluid-attenuated inversion recovery
MR images [3]. Gadolinium-enhanced T1-weighed MR is a
snapshot of contrast-enhancement in brain tissue and tumor after
contrast injection. However, assessment of tumor size based on
contrast enhancement after radiotherapy is not a specific tool to
predict treatment failure as changes in contrast enhancement can

Introduction
Patients with glioblastoma multiforme, the most common form
of adult brain tumors, have a median survival of approximately
12–15 months [1]. Radiotherapy has played an important role in
prolonging the survival of these patients since the 1970s [2].
Magnetic resonance (MR) and computed tomography (CT) are
currently the standard imaging modalities for assessing treatment

PLOS ONE | www.plosone.org

1

October 2014 | Volume 9 | Issue 10 | e109781

CT Perfusion Assessment of Glioma Response

of the caudate putamen [20]. The burr hole was sealed with bone
wax, and the scalp was closed with sutures.

occur in pathophysiological processes that disrupt the blood-brain
barrier. For instance, radiation-induced injury (e.g. radiationinduced necrosis and pseudoprogression) can mimic the appearance of tumor progression on post-gadolinium T1-weighted MR
[3].
Due to the poor survival rates, timely and accurate assessment
of response to radiation is important as treatment can be altered if
a non-responder to radiation can be identified early enough. In
preclinical studies, radiotherapy is usually delivered using a
technique called stereotactic radiosurgery (SRS). It is delivered
in one or a few large dose fractions of 8–30 Gy and results in
tumor growth delay and survival benefit [4–7]. Radiotherapy,
particularly SRS, can result in vascular damage in the irradiated
area [4,8–10], and radiosensitivity of tumor vasculature can
augment response to SRS [11].
Hypofractionation radiotherapy that also use a large dose per
fraction to treat patients with malignant gliomas is also an
attractive treatment strategy. Recently, clinical studies have
investigated the use of hypofractionated intensity-modulated
radiotherapy to treat these patients [12–14]. Hypofractionation
has some advantages over conventional fractionation. Hypofractionation is expected to increase the biological effect of radiation
due to increased cell damage resulting from a higher dose per
fraction [15]. It also reduces the effect of tumor repopulation by
reducing treatment time [16].
Since high-dose per fraction radiotherapy (e.g. SRS and
hypofractionated radiotherapy) can result in vascular damage,
imaging of tumor perfusion could be a promising biomarker of
response to this type of radiation treatment. The C6 rat glioma is a
widely used experimental model for the study of malignant glioma
[17], including the effects of SRS [6,7,9,10]. Tumor microcirculation can be noninvasively evaluated by CT or MR perfusion
imaging techniques. Both perfusion techniques acquire repeated
CT or MR images in succession after contrast injection; thus, the
wash-in and wash-out of the contrast in tissue can be modeled with
tracer kinetic analysis. CT perfusion imaging is a method that
allows quantitative mapping of blood flow (BF), blood volume
(BV), and permeability-surface area product (PS) [18,19]. CT
scanners and iodinated contrast agents are also widely available,
and they are ubiquitous in radiation oncology departments. The
purpose of this study was to evaluate vascular changes following
SRS using CT perfusion, and determine whether acute vascular
changes within one week of SRS is predictive of survival. In
addition, early (four days post-SRS) and late (eight weeks postSRS) histopathologic findings were examined.

Baseline CT Perfusion Imaging
All rats underwent the first CT perfusion scan on an average of
11 days (range, 7–16 days) after implantation of C6 glioma cells to
monitor tumor growth and prepare for SRS. The rats were
scanned using a clinical CT scanner (Discovery 750 HD, GE
Healthcare, Waukesha, WI). A two-phase CT perfusion scan,
guided by a prior non-contrast CT scan that identified
1661.25 mm thick sections to cover the entire brain, was
performed for each animal. The brain was scanned with high
resolution mode for 32 s at 1.4 s intervals during the first phase
and for a period of 165 s at 15 s intervals during the second phase.
A bolus of contrast (Isovue, Bracco Diagnostics Inc, Vaughan,
Canada, 300 mg iodine/ml, 2.5 mL/kg body weight) was injected
into the lateral tail vein at a rate of 0.13 mL/s at 3–4 s after the
start of the first phase. The scanning parameters were 80 kVp, 120
mAs, 10 cm field of view, and high-definition bone filter. The
visibly distinguishable spatial resolution was 1 line pair per
500 mm measured on a rat-size phantom [21].
CT perfusion images of the same slice were averaged over the
whole scan duration using the prototype version of CT perfusion
4D (GE Healthcare) to produce a set of contrast-enhanced images
called averaged CT images. The tumor diameter on the averaged
CT images was measured immediately after the scan. The rats
were assigned randomly to either the control group (N = 8) or the
SRS group (N = 25) once a tumor diameter of 4 mm was reached.

Stereotactic Radiosurgery
A custom-made plastic stereotactic frame was used to secure the
animals for treatment planning. A non-contrast helical CT scan
was performed (25 cm field-of-view, 80 kV, 110 mAs, 1.25 mm
slice thickness) for treatment planning. CT images were transferred to the Helical Tomotherapy Treatment Planning System
(Accuray Inc, Madison, WI, USA). Using the averaged CT images
for anatomical guidance, a dose of 12 Gy was prescribed to at least
80% of the contrast-enhanced tumor volume with the brainstem
receiving no more than 4 Gy and less than 10% of the normal
brain receiving more than 8 Gy. Figure S1 shows an example of a
treatment plan.
SRS was delivered using version 4.2 Hi-ART Helical
Tomotherapy (Accuray Inc., Sunnyvale, CA). The rats were fixed
in the same plastic stereotactic frame. A 3.5 MV CT study was
acquired prior to treatment and was co-registered with the
planning CT study. Then the couch position was shifted in the
lateral, anterior-posterior, and superior-inferior directions to
correct translational positioning errors. The rats were repositioned
in the stereotactic frame if there were rotational positioning errors.
The average SRS delivery time was 6 minutes (6 MV, 825 cGy/
min). Rats in the control group were put under anesthesia and
secured in the stereotactic frame for 6 minutes to mimic the
procedure without radiation.

Materials and Methods
This project was approved by the University Council on Animal
Care (Project #2010-009) at Western University.

C6 Glioma Model
Male Wistar rats weighing 300–400 g (N = 33) were used in this
study (Charles River Canada, age 8 to 10 weeks at surgery). The
animals were anaesthetized with 2% isoflurane during all
procedures. C6 glioma cells (CCL-107, American Type Culture
Collection, Manassas, VA) were cultured in F12k 15% horse
serum, 2.5% bovine serum, and 1% penicillin-streptomycin. For
the implantation of C6 glioma cells, each animal was secured into
a stereotactic surgical frame. After scalp incision at midline and
exposing the bregma, a 1 mm diameter burr hole was drilled at
1 mm anterior and 3 mm right of the bregma. A total of 106 C6
glioma cells were slowly injected for 5 minutes at a depth of 3–
4 mm from the skull surface, which corresponded to the location
PLOS ONE | www.plosone.org

Follow-up CT Perfusion Imaging
Rats in the SRS group were further assigned to either 1) acute
imaging group (N = 12) or 2) the longitudinal imaging group
(N = 13) (Figure S2). Rats in the acute imaging group were imaged
with CT perfusion at 4 days post-SRS, and were euthanized on the
same day. Rats in the longitudinal group and control group were
imaged for a maximum of 8 weeks post-SRS to monitor tumor
changes and survival. Rats were euthanized if they showed any of
the following signs and symptoms: weight loss of $15% from the
2
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Figure 1. Acute changes after stereotactic radiosurgery (SRS). (A) Acute CT perfusion changes between baseline and the fourth day after SRS.
Tumor is outlined in red and the peritumoral region is outlined in orange. For this animal, tumor relative blood flow (rBF) was 1.48 at baseline and it
decreased to 0.68 after SRS. Tumor relative blood volume (rBV) decreased from 1.70 to 0.78, while permeability surface-area (PS) decreased from 4.67
to 3.87 ml/min/100g. On the contrary, peritumoral rBF increased from 0.96 to 1.49, rBV increased from 1.06 to 1.52, and PS increased from 2.13 to
3.81 ml/min/100g. (B) Hematoxylin and Eosin (H&E) image of this animal after radiosurgery. Asterisk indicate the location of the tumor. (C) Magnified
H&E image of the tumor at the location indicated by the asterisk in (B).
doi:10.1371/journal.pone.0109781.g001

heaviest recorded weight, lethargy, refusal to eat, neurologic signs
such as one-sided limb weakness.

Image Analysis
Maps of BF, BV, and PS were generated using the prototype
version of CT perfusion 4D (GE Healthcare). The timeattenuation curve (TAC) from the carotid artery was selected as

Table 1. Acute changes (6 standard error) in CT perfusion parameters.

Percent Change (%)
Regions-of-interest
Tumor

Peritumoral

Treatment

Tumor volume

rBF

,##

rBV

PS

SRS

237.3613.2*

218.267.9*

223.167.6*

29.269.7

Control

95.1634.7*

213.169.3

26.469.4

7.4615.1

SRS

N/A

20.967.9*,#

28.767.7**,#

54.3611.6**

Control

N/A

25.065.3

2.065.0

13.9620.2

Abbreviations: SRS, stereotactic radiosurgery; rBF, relative blood flow; rBV, relative blood volume; PS, permeability-surface area product.
*Significantly change from baseline at P#0.05 level.
**Significantly change from to baseline at P#0.01 level.
#
Percent change significantly different than control animals at P#0.05 level.
##
Percent change significantly different than control animals at P#0.01 level.
doi:10.1371/journal.pone.0109781.t001
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Figure 2. Histological examples of stereotactic radiosurgery (SRS) effects. Representative Hematoxylin & Eosin images of (A) an untreated
control, (B) acute histological change at 4 days post-SRS, and (C) late histological change at 59 days post-SRS. Hypercellularity (four point star) and
pseudopalisading necrosis (five point star) are classic signs of grade IV glioma, and these were observed in the control animals. Hyalinized blood
vessels (arrow) and hypocellularity can be observed shortly after SRS. Regression of tumor and hyalinization of tissue were observed at a later stage
after SRS.
doi:10.1371/journal.pone.0109781.g002

the arterial input. The arterial TAC was deconvolved with tissue
TACs measured from 262 pixel blocks of CT images using the
Johnson-Wilson model to produce maps of BF, BV, and PS
[18,22]. Using the averaged CT images for anatomical guidance,
the lesion that was contrast-enhanced before SRS and the same
lesion that became non-enhanced after SRS was delineated as the
tumor (Figure 1). The region that is 2–3 mm adjacent to the
tumor that became contrast-enhanced after SRS was delineated as
the peritumoral region. The contralateral normal brain was also
delineated. Tumor volume, BF, BV, and PS in the tumor,
peritumoral region, and contralateral normal brain were measured. Mean BF and BV values were normalized to the
contralateral normal brain to obtain the relative BF (rBF) and
relative BV (rBV) values.

PLOS ONE | www.plosone.org

Histopathologic Examination
On the same day as the last CT perfusion scan, the animals
were euthanized with an overdose of potassium chloride. The
animals were perfusion-fixed with phosphate buffered saline
followed by 4% paraformaldehyde. The brains were removed
and fixed in 4% paraformaldehyde for 24 hours. The brain
specimens were sectioned into 3 mm thick blocks, paraffinembedded, then sectioned at 5 mm. Hematoxylin and eosin stain
(H&E) was applied on each section.
A blinded neuropathology resident (M.K.) examined all H&E
slides at different magnifications (20x and 40x) to evaluate
histologic signs of radiation damage. The presence of tumor was
evaluated as ‘‘no’’, ‘‘yes’’, or ‘‘diminished due to radiation effect’’.
‘‘Yes tumor’’ means the presence of a hypercellular lesion.
‘‘Diminished due to radiation effect’’ means the presence of a
circumscribed hypocellular lesion showing features of irradiation.
4
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33%
33% Diminished

Abbreviations: PPN, pseudopalisading necrosis; FN, fibrinoid necrosis; BN, background necrosis; EH, endothelial hyperplasia; HBV, hyalinized blood vessels.
doi:10.1371/journal.pone.0109781.t002

67% HBV
17% BN

67% EH

50% Increased
0% FN

55613
67% PPN
Non-responders (N = 6)

0% Diminished

50% Yes

4.661.5

33%

N/A
None
N/A
N/A
0% Yes
Responders (N = 7)

25% Diminished

14% HBV

0%
43% Increased

100% HBV
33% BN

0% EH

58% Increased
25% FN

5.863.0
75% Yes
Acute Histology (N = 12)

0% Diminished

PLOS ONE | www.plosone.org

‘‘No tumor’’ means the absence of a hypercellular lesion and a
hypocellular lesion. The diameter of each lesion (control and SRStreated animals) was measured. Tumor cellularity was defined as
1) hypercellular when less than 30% of the tumor area appeared
pale or major tumor was found, and 2) hypocellular when more
than 50% of the tumor area appeared pale excluding necrosis.
Tumor was graded based on the World Health Organization
criteria [23]. Tumor edema was defined as the presence of
extensive intracellular cytoplasmic swelling or intercellular spaces
between tumor cells. Peritumoral edema was defined as intracellular cytoplasmic swelling or presence of intercellular spaces and
reactive gliosis in the peritumoral region. Necrosis was described
as 1) pseudopalisading necrosis that indicates high-grade glioma, 2)
fibrinoid necrosis, or 3) background necrosis (neither pseudopalisading nor fibrinoid necrosis) that indicate post-radiation effect.
Presence of endothelial hyperplasia was recorded as a feature of
angiogenesis in high-grade glioma. Increased vascularity and
hyalinzed blood vessels were recorded as features of post-radiation
effect. Percentage of animals exhibiting these signs was calculated.
Mean percent necrosis by area was also calculated.
The brain sections were also stained with a Cy3-conjugated
mouse monoclonal anti-a-smooth muscle actin (a-SMA) (1:500,
clone 1A4, C6198, Sigma-Aldrich) to identify mature vessels [24–
26]. The slides were scanned using an Aperio ScanScope (Leica
Biosystems, Vista, CA), and images were captured using the
ImageScope software (version 11.2.0.780, Leica Biosystems, Vista,
CA). The a-SMA positive vessels were qualitatively classified as
intact or fragmented vessels. For each slide, a-SMA positive vessel
density was defined as the number of vessels that stained positive
for a-SMA in 6 separate fields (206) in the most vascular region of
the tumor and peritumoral region. An average of 14 separates
fields in the tumor and 14 separate fields in the peritumoral region
were examined for each animal. a-SMA positive vessels were
manually counted using the software JMicroVision [27]. Intact
and fragmented a-SMA positive vessel densities were measured
separately. The percentage of fragmented a-SMA positive vessels
was also recorded.

17%

0%

42%
25% HBV

25%

50% PPN

37619

58% EH

25%

0%
0%
75% EH

25% Increased

46627
88% PPN

13% FN

0%
Controls (N = 8)

88% Yes

7.364.0

Types of
Necrosis
Hypo-cellularity
Tumor Diameter
(mm)
Presence of Tumor

Table 2. Summary of histological finding on Hematoxylin and Eosin (H&E) specimens.

% Area
Necrosis

Vascularity

Tumor Edema

Peritumoral Edema

CT Perfusion Assessment of Glioma Response

Statistical Analysis
The Shapiro-Wilk test was used to test the normality of the data.
Temporal changes in the acute imaging group were tested by the
Wilcoxon signed-rank test. The end point of the longitudinal
imaging group was survival at 8 weeks post-SRS. The longitudinal
group was also subdivided into those that survived more than 15
days (responder group), and those that survived less than 15 days
post-SRS (non-responder group). The omnibus Kruskal-Wallis test
was used for comparisons between groups followed by the MannWhitney U test. The omnibus Friedman test was used for
longitudinal comparisons within-group followed by the Wilcoxon
signed-rank test. All data were reported as mean 6 standard error
of the mean (SE). Statistical comparisons were performed for the
first 4 time points (i.e. day 14 post-SRS) because all controls died
before the 5th time point (i.e. day 21 post-SRS).
Survival of the groups was compared using the log-rank test.
Spearman’s rank correlation was used to assess the associations
between different imaging parameters (tumor volume, rBF, rBV,
PS) and the percentage of fragmented a-SMA positive vessels. PS
is the product between microvessel surface area and permeability,
and BV has been shown to correlate with microvessel area [28].
Thus, we used the PS:BV ratio as a surrogate of permeability and
correlated this parameter with the percentage of fragmented aSMA positive vessels as well. Correlation between tumor volume
measured from averaged CT images and tumor diameter
measured from H&E histology was examined.
5
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Figure 3. a-smooth muscle actin (a-SMA) positive vessels in the normal brain, peritumoral region, and tumor of a control and a
treated animal after stereotactic radiosurgery (SRS). Intact a-SMA positive vessels were observed in control animals, but fragmented coverage
of vessels by a-SMA is mostly seen in treated animals (red arrow).
doi:10.1371/journal.pone.0109781.g003

each parameter in predicting survival were assessed. A P value#
0.05 was considered statistically significant.

We investigated whether the imaging parameters correlated
with overall survival, and whether these parameters on day 7 postSRS could predict survival. Each imaging parameter was assessed
by applying a threshold that is below the lower 50% confidence
interval (CI) boundary of the variations across all treated animals
derived from the between-subject variation on day 7 post-SRS.
This threshold was used to categorize each animal into two groups
(i.e. higher or lower than the threshold). Survivals of the different
groups were compared. The sensitivity, specificity, and accuracy of

Results
Acute Vascular Changes and Histopathologic Features
Irradiated rats received 12 Gy in the tumor and peritumoral
region, and different CT perfusion changes were observed in these
two regions. After SRS, tumor volume, rBF, and rBV decreased

Figure 4. Boxplots of intact and fragmented a-smooth muscle actin (a-SMA) positive vessel densities in (A) peritumoral region and
(B) tumor region for the control and SRS groups. Pairs with P,0.01 are connected by black lines.
doi:10.1371/journal.pone.0109781.g004

PLOS ONE | www.plosone.org

6

October 2014 | Volume 9 | Issue 10 | e109781

CT Perfusion Assessment of Glioma Response

Figure 5. Changes in (A) tumor volume, (B) relative blood flow (rBF), (C) relative blood volume (rBV), and (D) permeability-surface
area (PS) in the tumor for controls, responders, and non-responders. *Significantly different from baseline (Friedman test and Wilcoxonsigned rank test). {Significantly different from controls and #significantly different from non-responders (Kruskal-Wallis test followed by MannWhitney U test).
doi:10.1371/journal.pone.0109781.g005

significantly compared to baseline (P#0.05) while peritumoral
rBF, rBV, and PS increased significantly compared to baseline
(P#0.05) (Table 1). These opposite CT perfusion changes in the
tumor and peritumoral regions are illustrated in Figure 1A. For
the control animals, these parameters did not change significantly
from baseline (P.0.05).

H&E histological examination revealed that all tumors were
grade IV gliomas. Hypercellularity, mitosis, pseudopalisading
necrosis, and endothelial hyperplasia were observed as signs of
grade IV glioma in the control animals. For the acute imaging
group that received SRS, fibrinoid or background necrosis,
increased vascularity, and hyalinized blood vessels were identified.
Atypical nuclei, calcification, and gliosis were also observed in

Figure 6. Changes in (A) relative blood flow (rBF), (B) relative blood volume (rBV), and (C) permeability-surface area product (PS) in
the peritumoral region for controls, responders, and non-responders. *Significantly different from baseline (Friedman test and Wilcoxonsigned rank test). {Significantly different from controls (Kruskal-Wallis test followed by Mann-Whitney U test).
doi:10.1371/journal.pone.0109781.g006

PLOS ONE | www.plosone.org
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Figure 7. Kaplan-Meier plots of survival categorized by (A) response (B) tumor volume, (C) relative blood flow (rBF), (D) relative
blood volume (rBV), and (E) permeability-surface area product (PS). For each imaging parameter, two response groups were identified
based on whether the measured value was # lower 50% confidence interval of variations across all treated animals derived from the between-subject
variation on day 7 post-SRS. Those that met this criteria were ranked as ‘‘low’’ by applying this threshold, and the others were ranked as ‘‘high’’.
Animals with low rBF, rBV, and PS on day 7 post-SRS showed significantly longer survival than the rest of the treated animals (i.e. high rBF, rBV, and
PS) and control animals. *Significantly different from control group. {Significantly different from the other treated animals with a ‘‘high’’ value.
Significant at P#0.02 level (log-rank test).
doi:10.1371/journal.pone.0109781.g007

some lesions. Examples of H&E images of unirradiated tumor and
acute effects of SRS are demonstrated in Figure 2A and 2B,
respectively. A summary of histological findings is provided in
Table 2.
Immunohistochemical staining revealed fragmented a-SMA
positive vessels were identified mostly in the SRS-treated tumors
(Figure 3). Fragmented a-SMA positive vessel densities in the
tumor (P = 0.006) and peritumoral regions (P,0.001) were
significantly higher in the irradiated animals than the control
animals (Figure 4). In the tumor, a positive borderline significant
correlation between the percentage of fragmented a-SMA positive
vessels and PS:BV ratio was identified for the treated animals
(r = 0.58, P = 0.06) while a significant negative correlation was
found for the control animals (r = 20.84, P = 0.02, correlation
graphs not shown). However, the amount of fragmented a-SMA
positive vessels in the controls was very small (Figure 4). In the
peritumoral region of the treated animals, negative correlations
were found between the percentage of fragmented a-SMA positive
vessels with rBF (r = 20.62, P = 0.03) and rBV (r = 20.58,
P = 0.05).

responders. Shapiro-Wilk test showed the imaging data were not
from a normal distribution (P,0.05). Changes in tumor volume,
rBF, rBV, and PS of these three groups are shown in Figure 5.
At baseline, there was no statistical difference in tumor volume,
rBF, rBV, and PS (P.0.15). Similarly, there was no statistical
difference in peritumoral rBF, rBV, and PS (P.0.37). Significant
tumor growth was observed in the controls (Friedman P = 0.001,
Wilcoxon signed-rank P,0.03). Significant tumor shrinkage was
observed in the responders (Friedman P = 0.04, Wilcoxon signedrank P,0.05). There was no significant tumor volume change in
the non-responders. Tumor rBF in the responders was significantly
lower than the non-responders and controls on day 14 post-SRS
(Kruskal-Wallis P = 0.01, Mann-Whitney U P,0.04). Tumor rBV
in responders were significantly lower than the non-responders
and controls on day 4 (Kruskal-Wallis P = 0.04, Mann-Whitney U
P,0.04) and day 7 post-SRS (Kruskal-Wallis P = 0.01, MannWhitney U P = 0.01). Responders’ tumor PS was significantly
lower than the other groups on day 7 post-SRS (Kruskal-Wallis
P = 0.007, Mann-Whitney U P#0.008). Between-group differences and longitudinal changes in PS:BV ratio in the tumor were
not significant.
Figure 6 shows an elevation in peritumoral rBF in both
responders and non-responders on days 4 and 7 post-SRS
compared to the controls (Kruskal-Wallis P#0.006, MannWhitney U P#0.008). Significant elevation was observed in
peritumoral rBV of responders when compared to controls
(Kruskal-Wallis P,0.01, Mann-Whitney U P = 0.001), and a
similar trend was observed for peritumoral PS albeit not
significant. This elevation in CT perfusion parameters eventually

Treatment Response, Longitudinal Changes, and Late
Histopathologic Features
Median survival of the control group was 10 days post-baseline
scan (95% CI = 6–14 days), and median survival of the SRS group
was not reached (log-rank P,0.04). However, survival in the SRS
group was heterogeneous with 46% of the animals not surviving
for more than 15 days. We designated these relative low survival
animals as non-responders and animals with survival .15 days as
PLOS ONE | www.plosone.org
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preclinical results in that a higher rBV after the completion of
radiotherapy is associated with poor survival [33,34]. However,
the correlation between survival post-SRS and perfusion imaging
parameters is lacking in the clinical literature, and there is no
imaging biomarker to assess patients who might respond to SRS.
Our results provide corroborating evidence to support the
hypothesis that CT perfusion is an early biomarker of response
to SRS. Use of CT perfusion parameters to characterize tumor
vascular profiles and correlate with treatment response might
identify patients who would benefit from SRS or hypofractionation treatment schemes. The use of an early imaging biomarker to
assess response to SRS or hypofractionated treatment schemes in
randomized clinical trials might better define the role of altered
fractionation schemes in this group of patients.
From the acute imaging study, PS did not correlate with the
percentage of fragmented a-SMA positive vessels, this could
because PS is the product between permeability and surface area
of the endothelium [18]. Since BV has been shown to correlate
with microvessel area [28], we investigated the PS:BV ratio as a
surrogate marker of permeability. After SRS, a positive correlation
between PS:BV and the percentage of fragmented a-SMA positive
vessels points to the effect of radiation on the permeability of the
blood-tumor barrier. Vessels that are covered by SMA are mature
vessels [24–26], and tumor vessel maturity is associated radiation
resistance [8,35–36]. From our survival study, it is the permeability-surface area product (PS) that correlated with survival and not
the surrogate of permeability (i.e. PS:BV ratio). This suggests a
high surface area of SMA coverage after SRS is associated with
poor survival. Together, this points to a possible link between the
vessel SMA coverage and survival. We were unable to show a
correlation between survival and SMA coverage of mature vessels
directly since any assessment of tumor vessels would require the
sacrifice of animals. Further investigation into the direct associations between tumor PS and SMA coverage of mature vessels
with tumor response is warranted.
It is important to study the effect of radiation on the adjacent
normal brain tissue (i.e. peritumoral region) because it is usually
included in the irradiated volume that receives a significant dose of
radiation in clinical practice, particularly for linear acceleratorbased SRS. Complications and radiation-induced changes of brain
tissue, such as edema and blood-brain barrier breakage, after SRS
of arteriovenous malformations correlated with the volume of
irradiated tissue that received 12 Gy [37–38]. The effect of SRS on
peritumoral normal brain region in malignant glioma is not well
understood and seldom reported [10]. Zawaski et al. showed that
radiation caused significant changes in permeability and leukocyte-endothelial interactions in the peritumoral normal brain,
which were indicative of acute inflammatory reaction and
radiation-induced astrogliosis. Our study provides supporting
evidence by showing an increase in blood-brain barrier PS in
the peritumoral region. Therefore, a decrease in tumor rBF, rBV,
and PS in the tumor could indicate treatment response, an
increase in these parameters in the peritumoral region could be
indicative of acute radiation-induced inflammation.
A few limitations of this study must be considered. First, a
relationship exists between radiation effect and dose [2,4]. We
chose 12 Gy because this dose can be delivered safely using Helical
Tomotherapy, and it is used in the SRS boost of newly diagnosed
glioblastoma [29–30] and salvage therapy of recurrent glioblastoma for linear accelerator-based SRS [39]. Second, different tumor
cell lines display different radiosensitivities [40]. Therefore, doseresponse of vascular changes measured by CT perfusion in other
glioma models could be different. Thirdly, the sample size was
relatively small and all untreated rats and most of the non-

dissipated with time. Between-group differences and longitudinal
changes in PS:BV ratios in the peritumoral region were not
significant.
Histological examination revealed no presence of tumor in any
of the responders. Increased vascularity was the major sign of late
radiation-induced histologic change in the responders (Table 2).
Figure 2C shows an example of late radiation-induced damage
after the regression of the tumor. For the non-responders, tumors
were detected on H&E histology; pseudopalisading necrosis was
the major type of necrosis observed. Increased vascularity,
endothelial hyperplasia, and hyalinized blood vessels were also
observed. The correlations between tumor volume measured from
averaged CT and tumor diameter measured from H&E histology
were 0.88 (P = 0.01) for controls and 0.77 (P = 0.05) for nonresponders (P = 0.01). No tumor was identified on both averaged
CT images and H&E histology for the responders.

Early Prediction of Survival after Stereotactic
Radiosurgery
Tumor volume, rBF, rBV, PS, and PS:BV ratio at baseline and
on day 4 post-SRS did not correlate with overall survival.
However, tumor rBV (r = 20.61, P,0.05) and PS (r = 20.85,
P = 0.001) on day 7 post-SRS correlated with overall survival. We
evaluated whether each of the imaging parameter was predictive
of overall survival by grouping the treated animals based on the
measurement on day 7 post-SRS. Kaplan-Meier survival plots are
shown in Figure 7. SRS-treated animals with lower tumor rBF,
rBV, and PS had significantly longer survival than SRS-treated
animals with higher rBF, rBV, and PS (log-rank P#0.02). Treated
animals with smaller tumor volumes were associated with longer
survival than those with larger tumor volumes, but this was not
significant. Similarly, animals with a low PS:BV ratio were not
associated with significantly different survival than those with high
PS:BV ratio (graph not shown). In terms of predictive performance, both rBV and PS had the highest sensitivity (86%),
specificity (100%), and accuracy (92%). rBF had a sensitivity,
specificity, and accuracy of 71%, 100%, and 83%, respectively.
Tumor volume had a sensitivity, specificity, and accuracy of 57%,
80%, and 67%, respectively. The PS:BV ratio had sensitivity,
specificity, and accuracy of 67%, 60%, and 64%, respectively.

Discussion
Although radiotherapy offers an overall survival benefit at the
population level, accurate assessment of tumor response for each
patient is crucial for treatment modification if no response to
radiation is detected. Therefore, we need to develop non-invasive
imaging biomarkers as early indicators of response to radiation.
From preclinical studies, overall survival benefits post-SRS are
commonly reported, with some treated animals surviving substantially longer than others [4–6]. In our study, SRS demonstrated an
overall survival benefit and histological confirmation of radiationinduced damage. This survival benefit is consistent with previously
published studies [4–6]. Similar to previous studies, we observed
substantial heterogeneity in treatment response. We found that
CT perfusion can be a potential noninvasive imaging method to
predict response to SRS and that rBF, rBV, and PS showed better
predictive performance of survival than tumor volume.
In clinical studies, the survival benefit of SRS in combination
with fractionated radiotherapy is unclear with some studies
suggesting a 2-year overall survival benefit [29,30], while
randomized trials showed that SRS did not confer a survival
benefit over fractionated radiotherapy alone [31,32]. Current
clinical evidence from fractionated radiotherapy support our
PLOS ONE | www.plosone.org
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perfusion imaging in prospective clinical studies are necessary to
validate this technique as a predictive assay.

responders have died after the fourth CT perfusion scan. Thus, we
could not compare the imaging data between these groups at later
time points. Longitudinal tumoral and peritumoral changes
between the control animals, responders, and non-responders at
time points after day 21 post-SRS could be assessed if a larger
sample size was available. Finally, while we used stereotactic
techniques for radiation of the tumors, treatment volumes were
still large relative to the size of the rat brain with the irradiated
volume encompassing the ipsilateral cerebral hemisphere. Thus,
the volume of normal brain irradiated was larger than would be
the case in clinical radiosurgery treatments. It is possible that these
volume differences have contributed to the perfusion changes seen
in the peritumoral region.

Supporting Information
Figure S1 Example of a treatment plan. The tumor and

the 15, 12, and 8 Gy isodose lines are shown in the (A) coronal, (B)
axial, and (C) sagittal planes.
(TIF)
Figure S2

Experiment flowchart.

(TIF)
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